Navigation Links
SyntheMed Completes $4.0 Million Equity Placement
Date:10/1/2008

ISELIN, N.J., Oct. 1 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products and other surgical implants, announced today that it has completed the initial closing of a private placement in which it received $4.0 million in gross proceeds.

The transaction involved the issuance to investors of ten million units at $0.40 per unit. Each unit consists of one share of common stock and one three-year warrant entitling the holder to purchase one share of common stock at $0.50 per share. The transaction was placed through an agent with a consortium of European investors. The Company is authorized to raise an additional $2.0 million in the private placement on the same terms.

"We are very pleased with the positive response of the investors who participated in this placement," stated Robert Hickey, President and CEO. "The proceeds will allow us to advance the development of a portfolio of new anti-adhesion products and to prepare for the launch of REPEL-CV(R) Adhesion Barrier in the United States."

The securities offered in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Adhesions

Adhesions, or scar tissue, are fibrous structures that connect tissue surfaces that are not normally joined. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the length, cost and risk of the surgical procedure and can contribute to such post-operative complications as infertility, bowel obstruction, limited mobility and chronic pain.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedur
'/>"/>

SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
2. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
3. SyntheMed Files Universal Shelf Registration
4. SyntheMed to Present at the Acumen BioFin Conference
5. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. SAFC Pharma Completes Large-Scale API Manufacturing Expansion in Ireland
8. Novagali Pharma Completes a EUR15 Million Fund Raising
9. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
10. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
11. Roche completes acquisition of ARIUS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... January 22, 2015 Diagenode, Inc., ... as the Bioruptor® and complete solutions for epigenetics ... chromatin immunoprecipitation, alleviating the need for manual processing. ... needed for ChIP of histones or transcription factors ...
(Date:1/22/2015)... DIEGO , Jan. 22, 2015   Cypher ... and Sequenom, Inc. (NASDAQ: SQNM ), ... development agreement for next generation noninvasive prenatal tests ... genome interpretation technology, called Mantis™, to advance analysis ...
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4
... Demonstrated at HIMSS 2009BERKELEY HEIGHTS, N.J., April 6 ... ADAT ), a worldwide provider of secure ... announced that it has integrated Authentidate,s Inscrybe(TM) Healthcare ... hospital patient discharges. "Hospitals are looking to automate ...
... Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today ... (Spectrum) in connection with the sale of its 50% ... approximately $16.5 million that closed in March 2009. CTI ... related to this transaction, and the remaining $3.5 million, ...
... VIA Pharmaceuticals, Inc. (Nasdaq: VIAP ), ... for the treatment of cardiovascular and metabolic disease, today ... 31, 2009, from the staff of the NASDAQ Stock ... comply with NASDAQ Marketplace Rule 4310(c)(3). NASDAQ Marketplace ...
Cached Biology Technology:Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 2Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 3Authentidate Teams with Nortel to Enhance Hospital Patient Discharge and Placement Processes 4CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 2CTI Receives the Second Payment of $6.5 million Associated with the Sale of Interest in Zevalin Joint Venture 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 2VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 3VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ 4
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "The Global Watermarking and Fingerprinting ... http://photos.prnewswire.com/prnh/20130307/600769 This ... media watermarking and fingerprinting markets. Watermarking aims to ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
Breaking Biology News(10 mins):Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... Eating less during early pregnancy impaired fetal brain development in ... Health Science Center San Antonio reported today. The researchers ... of growth factors in the fetuses of mothers fed a ... a critical time window when many of the neurons as ...
... Mixing commonly used antibiotics with common blood pressure ... and induce shock in older patients, requiring hospitalization, ... ( Canadian Medical Association Journal ) (pre-embargo ... (erythromycin, clarithromycin and azithromycin) are among the most ...
... the January and February issues of the Journal ... and colleagues have extensively characterized a previously unidentified process ... membrane can be reversibly endocytosed. This massive endocytosis ... types with a range of different experimental manipulations, including ...
Cached Biology News:Reducing diet early in pregnancy stunts fetal brain development 2
BKBeta2 potassium channel Antigen: Fusion protein amino acids 1-41 (N-terminus) and 218-235 (C-terminus) of mouse BKBeta2 Accession Number: Q9CZM9...
POU domain, class 2, transcription factor 2,...
... The CellSensor CRE-bla HEK 293T cell ... control of the cAMP response element (CRE). ... construct was transduced into HEK 293T cells ... to isolate clones responsive to forskolin stimulation ...
activating transcription factor 4 (tax-responsive enhancer element B67),...
Biology Products: